English

UROGEN PHARMA LTD.

EDGAR

URGN Quarterly report (10-Q) · filed 2026-08-05

Annual consolidated revenue for 2025: about USD 109.8M, using the latest reported figures. The previous period, 2024, was about USD 90.4M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

72.5 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 72456000 USD Source

Operating margin

0.15%

2026 Q2 · %

Exact inputs and evidence

Operating Income: 111000 USD Source
Revenue: 72456000 USD Source

Operating cash flow

-33 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -78322000 USD Source
Operating Cash Flow: -45316000 USD Source

Free cash flow

-33.1 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -78322000 USD Source
Operating Cash Flow: -45316000 USD Source
Capital Expenditure: 114000 USD Source
Capital Expenditure: 54000 USD Source

Cash and cash equivalents: 79.1 million USD 2026-06-30 Source
Exact value

79133000 USD
Long-term debt including current maturities: 200 million USD 2026-06-30 Source
Exact value

200000000 USD
Shares outstanding: 48.9 million shares 2026-06-30 Source
Exact value

48900000 shares

Reported share-count change

5.84% · 2.7 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

46200000 shares · 2025-06-30· Source
48900000 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

189 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 27482000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 109788000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 71951000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 50959000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 72456000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-97.6 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -33347000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -153494000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -127130000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -23574000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -14351000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-159 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -124119000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -81849000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -162444000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -124119000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -45316000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -78322000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -45316000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

218 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 272000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 185000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 289000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 272000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 54000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 114000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 54000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-159 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -124119000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -81849000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -162444000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -124119000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -45316000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -78322000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -45316000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 272000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 185000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 289000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 272000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 54000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 114000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 54000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-05.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 10 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 10 of 11 periods available· newest 2025-12-31
Total liabilities: 10 of 11 periods available· newest 2025-12-31
Current assets: 10 of 11 periods available· newest 2025-12-31
Current liabilities: 10 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 10 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2025-12-31
Shares outstanding: 10 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+21.4%

Prior period

USD 90.4 million

2024-01-01 – 2024-12-31
Current period

USD 109.79 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

109788000 − 90398000 = 19390000 USD

90398000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
109788000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · UROGEN PHARMA LTD. · 2025-12-31 UROGEN PHARMA LTD. (edgar:1668243) Year-over-year change in Revenue: 19390000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 109788000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm#1893584 Filing: 000143774926006234 Input fundies:Revenue: 90398000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm#1894343 Filing: 000143774926006234
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 26.62 million

Prior period

−USD 126.87 million

2024-01-01 – 2024-12-31
Current period

−USD 153.49 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-153494000 − -126874000 = -26620000 USD

-126874000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-153494000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · UROGEN PHARMA LTD. · 2025-12-31 UROGEN PHARMA LTD. (edgar:1668243) Year-over-year change in Net income: -26620000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -153494000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm#1558892 Filing: 000143774926006234 Input fundies:NetIncome: -126874000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm#1559517 Filing: 000143774926006234
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 65.68 million

Prior period

−USD 96.77 million

2024-01-01 – 2024-12-31
Current period

−USD 162.44 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-162444000 − -96766000 = -65678000 USD

-96766000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-162444000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · UROGEN PHARMA LTD. · 2025-12-31 UROGEN PHARMA LTD. (edgar:1668243) Year-over-year change in Operating cash flow: -65678000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -162444000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm#1462138 Filing: 000143774926006234 Input fundies:OperatingCashFlow: -96766000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm#1462878 Filing: 000143774926006234
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-2%

Prior period

USD 295,000

2024-01-01 – 2024-12-31
Current period

USD 289,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

289000 − 295000 = -6000 USD

295000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
289000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · UROGEN PHARMA LTD. · 2025-12-31 UROGEN PHARMA LTD. (edgar:1668243) Year-over-year change in Capital expenditure: -6000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 289000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm#1468163 Filing: 000143774926006234 Input fundies:CapitalExpenditure: 295000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm#1468890 Filing: 000143774926006234
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 109.79 million 100% of revenue
Cost of revenue USD 12.45 million 11% of revenue
Operating expenses USD 222.2 million 202% of revenue
Operating income −USD 124.86 million −114% of revenue
Tax, interest and other Derived USD 28.63 million 26% of revenue
Net income −USD 153.49 million −140% of revenue

Cash

Operating cash flow −USD 162.44 million −148% of revenue
Capital expenditure USD 289,000 0.3% of revenue
Free cash flow Derived −USD 162.73 million −148% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Net loss: net income was −11% of revenue.
2017 Operating loss: operating costs were 345% of revenue.
2018 Operating loss: operating costs were 6,942% of revenue.
2019 Operating loss: operating costs were 608,311% of revenue.
2020 Operating loss: operating costs were 1,174% of revenue.
2021 Operating loss: operating costs were 292% of revenue.
2022 Operating loss: operating costs were 223% of revenue.
2023 Operating loss: operating costs were 179% of revenue.
2024 Operating loss: operating costs were 207% of revenue.
2025 Operating loss: operating costs were 214% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	17530000	16732000 Derived	798000	2739000 Derived	-1941000	3494000 Derived	Source 2016-01-01 – 2016-12-31: 17530000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: 798000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -1941000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: 4189000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 695000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	8158000	28108000 Derived	-19950000	50000 Derived	-20000000	-9839000 Derived	Source 2017-01-01 – 2017-12-31: 8158000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -19950000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -20000000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -9568000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 271000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	1128000	78308000 Derived	-77180000	-1523000 Derived	-75657000	-37894000 Derived	Source 2018-01-01 – 2018-12-31: 1128000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -77180000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -75657000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -37334000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 560000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	18000	109496000 Derived	-109478000	-4332000 Derived	-105146000	-71342000 Derived	Source 2019-01-01 – 2019-12-31: 18000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -109478000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -105146000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -71017000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 325000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	11799000	138538000 Derived	-126739000	1745000 Derived	-128484000	-107101000 Derived	Source 2020-01-01 – 2020-12-31: 11799000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -126739000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -128484000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -105886000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 1215000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	48042000	140334000 Derived	-92292000	18528000 Derived	-110820000	-85644000 Derived	Source 2021-01-01 – 2021-12-31: 48042000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -92292000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -110820000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -84892000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 752000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	64357000	143398000 Derived	-79041000	30742000 Derived	-109783000	-87813000 Derived	Source 2022-01-01 – 2022-12-31: 64357000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -79041000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -109783000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -87559000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 254000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	82713000	148249000 Derived	-65536000	36708000 Derived	-102244000	-76570000 Derived	Source 2023-01-01 – 2023-12-31: 82713000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -65536000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -102244000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -76376000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 194000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	90398000	187180000 Derived	-96782000	30092000 Derived	-126874000	-97061000 Derived	Source 2024-01-01 – 2024-12-31: 90398000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -96782000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -126874000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -96766000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 295000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	109788000	234651000 Derived	-124863000	28631000 Derived	-153494000	-162733000 Derived	Source 2025-01-01 – 2025-12-31: 109788000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -124863000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -153494000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -162444000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 289000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 109.8M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	17530000	Revenue: 17530000 Open source
20172017-12-31	Revenue	8158000	Revenue: 8158000 Open source
20182018-12-31	Revenue	1128000	Revenue: 1128000 Open source
20192019-12-31	Revenue	18000	Revenue: 18000 Open source
20202020-12-31	Revenue	11799000	Revenue: 11799000 Open source
20212021-12-31	Revenue	48042000	Revenue: 48042000 Open source
20222022-12-31	Revenue	64357000	Revenue: 64357000 Open source
20232023-12-31	Revenue	82713000	Revenue: 82713000 Open source
20242024-12-31	Revenue	90398000	Revenue: 90398000 Open source
20252025-12-31	Revenue	109788000	Revenue: 109788000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

21.4% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 17530000 Open source
20172017-12-31	Year over year	-53.5%	Revenue: 8158000 Open source Revenue: 17530000 Open source
20182018-12-31	Year over year	-86.2%	Revenue: 1128000 Open source Revenue: 8158000 Open source
20192019-12-31	Year over year	-98.4%	Revenue: 18000 Open source Revenue: 1128000 Open source
20202020-12-31	Year over year	65,450%	Revenue: 11799000 Open source Revenue: 18000 Open source
20212021-12-31	Year over year	307.2%	Revenue: 48042000 Open source Revenue: 11799000 Open source
20222022-12-31	Year over year	34%	Revenue: 64357000 Open source Revenue: 48042000 Open source
20232023-12-31	Year over year	28.5%	Revenue: 82713000 Open source Revenue: 64357000 Open source
20242024-12-31	Year over year	9.3%	Revenue: 90398000 Open source Revenue: 82713000 Open source
20252025-12-31	Year over year	21.4%	Revenue: 109788000 Open source Revenue: 90398000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -113.7% 2025

Net margin -139.8% 2025

Free cash flow margin -148.2% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	4.6%	Operating Income: 798000 Open source Revenue: 17530000 Open source
20172017-12-31	Operating margin	-244.5%	Operating Income: -19950000 Open source Revenue: 8158000 Open source
20182018-12-31	Operating margin	-6,842.2%	Operating Income: -77180000 Open source Revenue: 1128000 Open source
20192019-12-31	Operating margin	-608,211.1%	Operating Income: -109478000 Open source Revenue: 18000 Open source
20202020-12-31	Operating margin	-1,074.2%	Operating Income: -126739000 Open source Revenue: 11799000 Open source
20212021-12-31	Operating margin	-192.1%	Operating Income: -92292000 Open source Revenue: 48042000 Open source
20222022-12-31	Operating margin	-122.8%	Operating Income: -79041000 Open source Revenue: 64357000 Open source
20232023-12-31	Operating margin	-79.2%	Operating Income: -65536000 Open source Revenue: 82713000 Open source
20242024-12-31	Operating margin	-107.1%	Operating Income: -96782000 Open source Revenue: 90398000 Open source
20252025-12-31	Operating margin	-113.7%	Operating Income: -124863000 Open source Revenue: 109788000 Open source
20162016-12-31	Net margin	-11.1%	Net Income: -1941000 Open source Revenue: 17530000 Open source
20172017-12-31	Net margin	-245.2%	Net Income: -20000000 Open source Revenue: 8158000 Open source
20182018-12-31	Net margin	-6,707.2%	Net Income: -75657000 Open source Revenue: 1128000 Open source
20192019-12-31	Net margin	-584,144.4%	Net Income: -105146000 Open source Revenue: 18000 Open source
20202020-12-31	Net margin	-1,088.9%	Net Income: -128484000 Open source Revenue: 11799000 Open source
20212021-12-31	Net margin	-230.7%	Net Income: -110820000 Open source Revenue: 48042000 Open source
20222022-12-31	Net margin	-170.6%	Net Income: -109783000 Open source Revenue: 64357000 Open source
20232023-12-31	Net margin	-123.6%	Net Income: -102244000 Open source Revenue: 82713000 Open source
20242024-12-31	Net margin	-140.4%	Net Income: -126874000 Open source Revenue: 90398000 Open source
20252025-12-31	Net margin	-139.8%	Net Income: -153494000 Open source Revenue: 109788000 Open source
20162016-12-31	Free cash flow margin	19.9%	Revenue: 17530000 Open source Operating Cash Flow: 4189000 Open source Capital Expenditure: 695000 Open source
20172017-12-31	Free cash flow margin	-120.6%	Revenue: 8158000 Open source Operating Cash Flow: -9568000 Open source Capital Expenditure: 271000 Open source
20182018-12-31	Free cash flow margin	-3,359.4%	Revenue: 1128000 Open source Operating Cash Flow: -37334000 Open source Capital Expenditure: 560000 Open source
20192019-12-31	Free cash flow margin	-396,344.4%	Revenue: 18000 Open source Operating Cash Flow: -71017000 Open source Capital Expenditure: 325000 Open source
20202020-12-31	Free cash flow margin	-907.7%	Revenue: 11799000 Open source Operating Cash Flow: -105886000 Open source Capital Expenditure: 1215000 Open source
20212021-12-31	Free cash flow margin	-178.3%	Revenue: 48042000 Open source Operating Cash Flow: -84892000 Open source Capital Expenditure: 752000 Open source
20222022-12-31	Free cash flow margin	-136.4%	Revenue: 64357000 Open source Operating Cash Flow: -87559000 Open source Capital Expenditure: 254000 Open source
20232023-12-31	Free cash flow margin	-92.6%	Revenue: 82713000 Open source Operating Cash Flow: -76376000 Open source Capital Expenditure: 194000 Open source
20242024-12-31	Free cash flow margin	-107.4%	Revenue: 90398000 Open source Operating Cash Flow: -96766000 Open source Capital Expenditure: 295000 Open source
20252025-12-31	Free cash flow margin	-148.2%	Revenue: 109788000 Open source Operating Cash Flow: -162444000 Open source Capital Expenditure: 289000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -162.4M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	4189000	Operating Cash Flow: 4189000 Open source
20172017-12-31	Operating cash flow	-9568000	Operating Cash Flow: -9568000 Open source
20182018-12-31	Operating cash flow	-37334000	Operating Cash Flow: -37334000 Open source
20192019-12-31	Operating cash flow	-71017000	Operating Cash Flow: -71017000 Open source
20202020-12-31	Operating cash flow	-105886000	Operating Cash Flow: -105886000 Open source
20212021-12-31	Operating cash flow	-84892000	Operating Cash Flow: -84892000 Open source
20222022-12-31	Operating cash flow	-87559000	Operating Cash Flow: -87559000 Open source
20232023-12-31	Operating cash flow	-76376000	Operating Cash Flow: -76376000 Open source
20242024-12-31	Operating cash flow	-96766000	Operating Cash Flow: -96766000 Open source
20252025-12-31	Operating cash flow	-162444000	Operating Cash Flow: -162444000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -162.7M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	3494000	Operating Cash Flow: 4189000 Open source Capital Expenditure: 695000 Open source
20172017-12-31	Free cash flow	-9839000	Operating Cash Flow: -9568000 Open source Capital Expenditure: 271000 Open source
20182018-12-31	Free cash flow	-37894000	Operating Cash Flow: -37334000 Open source Capital Expenditure: 560000 Open source
20192019-12-31	Free cash flow	-71342000	Operating Cash Flow: -71017000 Open source Capital Expenditure: 325000 Open source
20202020-12-31	Free cash flow	-107101000	Operating Cash Flow: -105886000 Open source Capital Expenditure: 1215000 Open source
20212021-12-31	Free cash flow	-85644000	Operating Cash Flow: -84892000 Open source Capital Expenditure: 752000 Open source
20222022-12-31	Free cash flow	-87813000	Operating Cash Flow: -87559000 Open source Capital Expenditure: 254000 Open source
20232023-12-31	Free cash flow	-76570000	Operating Cash Flow: -76376000 Open source Capital Expenditure: 194000 Open source
20242024-12-31	Free cash flow	-97061000	Operating Cash Flow: -96766000 Open source Capital Expenditure: 295000 Open source
20252025-12-31	Free cash flow	-162733000	Operating Cash Flow: -162444000 Open source Capital Expenditure: 289000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

152.6% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	29.3%	Total Liabilities: 6749000 Open source Total Assets: 23056000 Open source
20172017-12-31	Liabilities / assets	9.3%	Total Liabilities: 7035000 Open source Total Assets: 75550000 Open source
20182018-12-31	Liabilities / assets	13%	Total Liabilities: 13465000 Open source Total Assets: 103559000 Open source
20192019-12-31	Liabilities / assets	10.9%	Total Liabilities: 22086000 Open source Total Assets: 202388000 Open source
20202020-12-31	Liabilities / assets	21%	Total Liabilities: 25650000 Open source Total Assets: 122005000 Open source
20212021-12-31	Liabilities / assets	93%	Total Liabilities: 111333000 Open source Total Assets: 119746000 Open source
20222022-12-31	Liabilities / assets	165.9%	Total Liabilities: 224980000 Open source Total Assets: 135619000 Open source
20232023-12-31	Liabilities / assets	136.6%	Total Liabilities: 243523000 Open source Total Assets: 178311000 Open source
20242024-12-31	Liabilities / assets	103.1%	Total Liabilities: 294514000 Open source Total Assets: 285711000 Open source
20252025-12-31	Liabilities / assets	152.6%	Total Liabilities: 305929000 Open source Total Assets: 200455000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

4.01× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	7.03×	Current Assets: 22041000 Open source Current Liabilities: 3137000 Open source
20172017-12-31	Current assets / current liabilities	10.59×	Current Assets: 74472000 Open source Current Liabilities: 7035000 Open source
20182018-12-31	Current assets / current liabilities	7.59×	Current Assets: 102243000 Open source Current Liabilities: 13465000 Open source
20192019-12-31	Current assets / current liabilities	7.63×	Current Assets: 148634000 Open source Current Liabilities: 19482000 Open source
20202020-12-31	Current assets / current liabilities	5.39×	Current Assets: 115619000 Open source Current Liabilities: 21436000 Open source
20212021-12-31	Current assets / current liabilities	5.11×	Current Assets: 114390000 Open source Current Liabilities: 22380000 Open source
20222022-12-31	Current assets / current liabilities	5.39×	Current Assets: 128907000 Open source Current Liabilities: 23916000 Open source
20232023-12-31	Current assets / current liabilities	5.42×	Current Assets: 169186000 Open source Current Liabilities: 31212000 Open source
20242024-12-31	Current assets / current liabilities	6.01×	Current Assets: 276135000 Open source Current Liabilities: 45949000 Open source
20252025-12-31	Current assets / current liabilities	4.01×	Current Assets: 186024000 Open source Current Liabilities: 46418000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 1.94 million Exact value Exact value: -1941000 USD 2016-01-01 – 2016-12-31: -1941000 USD Inspect Net Income Open source Share or cite Citation for Net Income · UROGEN PHARMA LTD. · 2016-12-31 UROGEN PHARMA LTD. (edgar:1668243) Net Income: -1941000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1941000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459019005323/urgn-20181231.xml#135625 Filing: 000156459019005323 The citation records this snapshot. The page link may show a newer release later.	USD 4.19 million Exact value Exact value: 4189000 USD 2016-01-01 – 2016-12-31: 4189000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · UROGEN PHARMA LTD. · 2016-12-31 UROGEN PHARMA LTD. (edgar:1668243) Operating Cash Flow: 4189000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 4189000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459019005323/urgn-20181231.xml#156892 Filing: 000156459019005323 The citation records this snapshot. The page link may show a newer release later.	USD 695,000 Exact value Exact value: 695000 USD 2016-01-01 – 2016-12-31: 695000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · UROGEN PHARMA LTD. · 2016-12-31 UROGEN PHARMA LTD. (edgar:1668243) Capital Expenditure: 695000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 695000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459019005323/urgn-20181231.xml#158510 Filing: 000156459019005323 The citation records this snapshot. The page link may show a newer release later.	USD 3.49 million Calculation and evidence 4189000 − 695000 USD Exact free cash flow: 3494000 USD 2016-01-01 – 2016-12-31: 4189000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 695000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · UROGEN PHARMA LTD. · 2016-12-31 UROGEN PHARMA LTD. (edgar:1668243) Free cash flow: 3494000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 4189000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459019005323/urgn-20181231.xml#156892 Filing: 000156459019005323 Input fundies:CapitalExpenditure: 695000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459019005323/urgn-20181231.xml#158510 Filing: 000156459019005323 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 20 million Exact value Exact value: -20000000 USD 2017-01-01 – 2017-12-31: -20000000 USD Inspect Net Income Open source Share or cite Citation for Net Income · UROGEN PHARMA LTD. · 2017-12-31 UROGEN PHARMA LTD. (edgar:1668243) Net Income: -20000000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -20000000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459020007970/urgn-10k_20191231.htm#2663374 Filing: 000156459020007970 The citation records this snapshot. The page link may show a newer release later.	−USD 9.57 million Exact value Exact value: -9568000 USD 2017-01-01 – 2017-12-31: -9568000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · UROGEN PHARMA LTD. · 2017-12-31 UROGEN PHARMA LTD. (edgar:1668243) Operating Cash Flow: -9568000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9568000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459020007970/urgn-10k_20191231.htm#2334689 Filing: 000156459020007970 The citation records this snapshot. The page link may show a newer release later.	USD 271,000 Exact value Exact value: 271000 USD 2017-01-01 – 2017-12-31: 271000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · UROGEN PHARMA LTD. · 2017-12-31 UROGEN PHARMA LTD. (edgar:1668243) Capital Expenditure: 271000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 271000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459020007970/urgn-10k_20191231.htm#2367873 Filing: 000156459020007970 The citation records this snapshot. The page link may show a newer release later.	−USD 9.84 million Calculation and evidence -9568000 − 271000 USD Exact free cash flow: -9839000 USD 2017-01-01 – 2017-12-31: -9568000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 271000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · UROGEN PHARMA LTD. · 2017-12-31 UROGEN PHARMA LTD. (edgar:1668243) Free cash flow: -9839000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9568000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459020007970/urgn-10k_20191231.htm#2334689 Filing: 000156459020007970 Input fundies:CapitalExpenditure: 271000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459020007970/urgn-10k_20191231.htm#2367873 Filing: 000156459020007970 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 75.66 million Exact value Exact value: -75657000 USD 2018-01-01 – 2018-12-31: -75657000 USD Inspect Net Income Open source Share or cite Citation for Net Income · UROGEN PHARMA LTD. · 2018-12-31 UROGEN PHARMA LTD. (edgar:1668243) Net Income: -75657000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -75657000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459020007970/urgn-10k_20191231.htm#3624700 Filing: 000156459020007970 The citation records this snapshot. The page link may show a newer release later.	−USD 37.33 million Exact value Exact value: -37334000 USD 2018-01-01 – 2018-12-31: -37334000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · UROGEN PHARMA LTD. · 2018-12-31 UROGEN PHARMA LTD. (edgar:1668243) Operating Cash Flow: -37334000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -37334000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459020007970/urgn-10k_20191231.htm#2332720 Filing: 000156459020007970 The citation records this snapshot. The page link may show a newer release later.	USD 560,000 Exact value Exact value: 560000 USD 2018-01-01 – 2018-12-31: 560000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · UROGEN PHARMA LTD. · 2018-12-31 UROGEN PHARMA LTD. (edgar:1668243) Capital Expenditure: 560000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 560000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459020007970/urgn-10k_20191231.htm#2366009 Filing: 000156459020007970 The citation records this snapshot. The page link may show a newer release later.	−USD 37.89 million Calculation and evidence -37334000 − 560000 USD Exact free cash flow: -37894000 USD 2018-01-01 – 2018-12-31: -37334000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 560000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · UROGEN PHARMA LTD. · 2018-12-31 UROGEN PHARMA LTD. (edgar:1668243) Free cash flow: -37894000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -37334000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459020007970/urgn-10k_20191231.htm#2332720 Filing: 000156459020007970 Input fundies:CapitalExpenditure: 560000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459020007970/urgn-10k_20191231.htm#2366009 Filing: 000156459020007970 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 105.15 million Exact value Exact value: -105146000 USD 2019-01-01 – 2019-12-31: -105146000 USD Inspect Net Income Open source Share or cite Citation for Net Income · UROGEN PHARMA LTD. · 2019-12-31 UROGEN PHARMA LTD. (edgar:1668243) Net Income: -105146000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -105146000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459021014016/urgn-10k_20201231.htm#2012550 Filing: 000156459021014016 The citation records this snapshot. The page link may show a newer release later.	−USD 71.02 million Exact value Exact value: -71017000 USD 2019-01-01 – 2019-12-31: -71017000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · UROGEN PHARMA LTD. · 2019-12-31 UROGEN PHARMA LTD. (edgar:1668243) Operating Cash Flow: -71017000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -71017000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459021014016/urgn-10k_20201231.htm#1859573 Filing: 000156459021014016 The citation records this snapshot. The page link may show a newer release later.	USD 325,000 Exact value Exact value: 325000 USD 2019-01-01 – 2019-12-31: 325000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · UROGEN PHARMA LTD. · 2019-12-31 UROGEN PHARMA LTD. (edgar:1668243) Capital Expenditure: 325000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 325000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459021014016/urgn-10k_20201231.htm#1879136 Filing: 000156459021014016 The citation records this snapshot. The page link may show a newer release later.	−USD 71.34 million Calculation and evidence -71017000 − 325000 USD Exact free cash flow: -71342000 USD 2019-01-01 – 2019-12-31: -71017000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 325000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · UROGEN PHARMA LTD. · 2019-12-31 UROGEN PHARMA LTD. (edgar:1668243) Free cash flow: -71342000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -71017000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459021014016/urgn-10k_20201231.htm#1859573 Filing: 000156459021014016 Input fundies:CapitalExpenditure: 325000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000156459021014016/urgn-10k_20201231.htm#1879136 Filing: 000156459021014016 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 128.48 million Exact value Exact value: -128484000 USD 2020-01-01 – 2020-12-31: -128484000 USD Inspect Net Income Open source Share or cite Citation for Net Income · UROGEN PHARMA LTD. · 2020-12-31 UROGEN PHARMA LTD. (edgar:1668243) Net Income: -128484000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -128484000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774922006778/urgn20211231_10k.htm#1347090 Filing: 000143774922006778 The citation records this snapshot. The page link may show a newer release later.	−USD 105.89 million Exact value Exact value: -105886000 USD 2020-01-01 – 2020-12-31: -105886000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · UROGEN PHARMA LTD. · 2020-12-31 UROGEN PHARMA LTD. (edgar:1668243) Operating Cash Flow: -105886000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -105886000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774922006778/urgn20211231_10k.htm#1263057 Filing: 000143774922006778 The citation records this snapshot. The page link may show a newer release later.	USD 1.22 million Exact value Exact value: 1215000 USD 2020-01-01 – 2020-12-31: 1215000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · UROGEN PHARMA LTD. · 2020-12-31 UROGEN PHARMA LTD. (edgar:1668243) Capital Expenditure: 1215000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1215000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774922006778/urgn20211231_10k.htm#1270214 Filing: 000143774922006778 The citation records this snapshot. The page link may show a newer release later.	−USD 107.1 million Calculation and evidence -105886000 − 1215000 USD Exact free cash flow: -107101000 USD 2020-01-01 – 2020-12-31: -105886000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1215000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · UROGEN PHARMA LTD. · 2020-12-31 UROGEN PHARMA LTD. (edgar:1668243) Free cash flow: -107101000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -105886000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774922006778/urgn20211231_10k.htm#1263057 Filing: 000143774922006778 Input fundies:CapitalExpenditure: 1215000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774922006778/urgn20211231_10k.htm#1270214 Filing: 000143774922006778 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 110.82 million Exact value Exact value: -110820000 USD 2021-01-01 – 2021-12-31: -110820000 USD Inspect Net Income Open source Share or cite Citation for Net Income · UROGEN PHARMA LTD. · 2021-12-31 UROGEN PHARMA LTD. (edgar:1668243) Net Income: -110820000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -110820000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774923007710/urgn20221231_10k.htm#1380040 Filing: 000143774923007710 The citation records this snapshot. The page link may show a newer release later.	−USD 84.89 million Exact value Exact value: -84892000 USD 2021-01-01 – 2021-12-31: -84892000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · UROGEN PHARMA LTD. · 2021-12-31 UROGEN PHARMA LTD. (edgar:1668243) Operating Cash Flow: -84892000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -84892000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774923007710/urgn20221231_10k.htm#1294405 Filing: 000143774923007710 The citation records this snapshot. The page link may show a newer release later.	USD 752,000 Exact value Exact value: 752000 USD 2021-01-01 – 2021-12-31: 752000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · UROGEN PHARMA LTD. · 2021-12-31 UROGEN PHARMA LTD. (edgar:1668243) Capital Expenditure: 752000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 752000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774923007710/urgn20221231_10k.htm#1301554 Filing: 000143774923007710 The citation records this snapshot. The page link may show a newer release later.	−USD 85.64 million Calculation and evidence -84892000 − 752000 USD Exact free cash flow: -85644000 USD 2021-01-01 – 2021-12-31: -84892000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 752000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · UROGEN PHARMA LTD. · 2021-12-31 UROGEN PHARMA LTD. (edgar:1668243) Free cash flow: -85644000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -84892000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774923007710/urgn20221231_10k.htm#1294405 Filing: 000143774923007710 Input fundies:CapitalExpenditure: 752000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774923007710/urgn20221231_10k.htm#1301554 Filing: 000143774923007710 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 109.78 million Exact value Exact value: -109783000 USD 2022-01-01 – 2022-12-31: -109783000 USD Inspect Net Income Open source Share or cite Citation for Net Income · UROGEN PHARMA LTD. · 2022-12-31 UROGEN PHARMA LTD. (edgar:1668243) Net Income: -109783000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -109783000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774924007753/urgn20231231_10k.htm#1452565 Filing: 000143774924007753 The citation records this snapshot. The page link may show a newer release later.	−USD 87.56 million Exact value Exact value: -87559000 USD 2022-01-01 – 2022-12-31: -87559000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · UROGEN PHARMA LTD. · 2022-12-31 UROGEN PHARMA LTD. (edgar:1668243) Operating Cash Flow: -87559000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -87559000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774924007753/urgn20231231_10k.htm#1365606 Filing: 000143774924007753 The citation records this snapshot. The page link may show a newer release later.	USD 254,000 Exact value Exact value: 254000 USD 2022-01-01 – 2022-12-31: 254000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · UROGEN PHARMA LTD. · 2022-12-31 UROGEN PHARMA LTD. (edgar:1668243) Capital Expenditure: 254000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 254000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774924007753/urgn20231231_10k.htm#1370855 Filing: 000143774924007753 The citation records this snapshot. The page link may show a newer release later.	−USD 87.81 million Calculation and evidence -87559000 − 254000 USD Exact free cash flow: -87813000 USD 2022-01-01 – 2022-12-31: -87559000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 254000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · UROGEN PHARMA LTD. · 2022-12-31 UROGEN PHARMA LTD. (edgar:1668243) Free cash flow: -87813000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -87559000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774924007753/urgn20231231_10k.htm#1365606 Filing: 000143774924007753 Input fundies:CapitalExpenditure: 254000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774924007753/urgn20231231_10k.htm#1370855 Filing: 000143774924007753 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 102.24 million Exact value Exact value: -102244000 USD 2023-01-01 – 2023-12-31: -102244000 USD Inspect Net Income Open source Share or cite Citation for Net Income · UROGEN PHARMA LTD. · 2023-12-31 UROGEN PHARMA LTD. (edgar:1668243) Net Income: -102244000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -102244000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm#2155325 Filing: 000143774925006842 The citation records this snapshot. The page link may show a newer release later.	−USD 76.38 million Exact value Exact value: -76376000 USD 2023-01-01 – 2023-12-31: -76376000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · UROGEN PHARMA LTD. · 2023-12-31 UROGEN PHARMA LTD. (edgar:1668243) Operating Cash Flow: -76376000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -76376000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm#1428493 Filing: 000143774925006842 The citation records this snapshot. The page link may show a newer release later.	USD 194,000 Exact value Exact value: 194000 USD 2023-01-01 – 2023-12-31: 194000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · UROGEN PHARMA LTD. · 2023-12-31 UROGEN PHARMA LTD. (edgar:1668243) Capital Expenditure: 194000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 194000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm#1433744 Filing: 000143774925006842 The citation records this snapshot. The page link may show a newer release later.	−USD 76.57 million Calculation and evidence -76376000 − 194000 USD Exact free cash flow: -76570000 USD 2023-01-01 – 2023-12-31: -76376000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 194000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · UROGEN PHARMA LTD. · 2023-12-31 UROGEN PHARMA LTD. (edgar:1668243) Free cash flow: -76570000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -76376000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm#1428493 Filing: 000143774925006842 Input fundies:CapitalExpenditure: 194000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm#1433744 Filing: 000143774925006842 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 126.87 million Exact value Exact value: -126874000 USD 2024-01-01 – 2024-12-31: -126874000 USD Inspect Net Income Open source Share or cite Citation for Net Income · UROGEN PHARMA LTD. · 2024-12-31 UROGEN PHARMA LTD. (edgar:1668243) Net Income: -126874000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -126874000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm#1559517 Filing: 000143774926006234 The citation records this snapshot. The page link may show a newer release later.	−USD 96.77 million Exact value Exact value: -96766000 USD 2024-01-01 – 2024-12-31: -96766000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · UROGEN PHARMA LTD. · 2024-12-31 UROGEN PHARMA LTD. (edgar:1668243) Operating Cash Flow: -96766000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -96766000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm#1462878 Filing: 000143774926006234 The citation records this snapshot. The page link may show a newer release later.	USD 295,000 Exact value Exact value: 295000 USD 2024-01-01 – 2024-12-31: 295000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · UROGEN PHARMA LTD. · 2024-12-31 UROGEN PHARMA LTD. (edgar:1668243) Capital Expenditure: 295000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 295000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm#1468890 Filing: 000143774926006234 The citation records this snapshot. The page link may show a newer release later.	−USD 97.06 million Calculation and evidence -96766000 − 295000 USD Exact free cash flow: -97061000 USD 2024-01-01 – 2024-12-31: -96766000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 295000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · UROGEN PHARMA LTD. · 2024-12-31 UROGEN PHARMA LTD. (edgar:1668243) Free cash flow: -97061000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -96766000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm#1462878 Filing: 000143774926006234 Input fundies:CapitalExpenditure: 295000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm#1468890 Filing: 000143774926006234 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 153.49 million Exact value Exact value: -153494000 USD 2025-01-01 – 2025-12-31: -153494000 USD Inspect Net Income Open source Share or cite Citation for Net Income · UROGEN PHARMA LTD. · 2025-12-31 UROGEN PHARMA LTD. (edgar:1668243) Net Income: -153494000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -153494000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm#1558892 Filing: 000143774926006234 The citation records this snapshot. The page link may show a newer release later.	−USD 162.44 million Exact value Exact value: -162444000 USD 2025-01-01 – 2025-12-31: -162444000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · UROGEN PHARMA LTD. · 2025-12-31 UROGEN PHARMA LTD. (edgar:1668243) Operating Cash Flow: -162444000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -162444000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm#1462138 Filing: 000143774926006234 The citation records this snapshot. The page link may show a newer release later.	USD 289,000 Exact value Exact value: 289000 USD 2025-01-01 – 2025-12-31: 289000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · UROGEN PHARMA LTD. · 2025-12-31 UROGEN PHARMA LTD. (edgar:1668243) Capital Expenditure: 289000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 289000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm#1468163 Filing: 000143774926006234 The citation records this snapshot. The page link may show a newer release later.	−USD 162.73 million Calculation and evidence -162444000 − 289000 USD Exact free cash flow: -162733000 USD 2025-01-01 – 2025-12-31: -162444000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 289000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · UROGEN PHARMA LTD. · 2025-12-31 UROGEN PHARMA LTD. (edgar:1668243) Free cash flow: -162733000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:32:32Z Snapshot: 4f315e86b9ce69d7963b1926466a4189374769cb9fb0657ea7b3e98b4b5cc255 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1668243?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -162444000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm#1462138 Filing: 000143774926006234 Input fundies:CapitalExpenditure: 289000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm#1468163 Filing: 000143774926006234 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

77 filings · 2,536 latest values · 2,536 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001668243, 1668243, URGN, edgar:1668243

Also known as UROGEN PHARMA LTD., UroGen Pharma Ltd.

UROGEN PHARMA LTD.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation